Molecular subgroups of adult medulloblastoma: a long-term single-institution study by Zhao, Fu et al.
Molecular subgroups of adult medulloblastoma: a long-term
single-institution study
Fu Zhao, Hiroko Ohgaki, Lei Xu, Felice Giangaspero, Chunde Li, Peng Li, Zhijun Yang, Bo Wang, Xingchao Wang,
Zhenmin Wang, Lin Ai, Jing Zhang, Lin Luo, and Pinan Liu
Neural Reconstructional Department, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (F.Z., J.Z., P.L.);
Department of Pathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China (L.L.); Department of
Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (F.Z., C.L., P.L., Z.Y., B.W., X.W., Z.W., P.L.); Department
of Imaging and Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (L.A.); Section of Molecular
Pathology, International Agency for Research on Cancer, World Health Organization, Lyon, France (H.O.); Edwin L. Steele Laboratories
for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston,
Massachusetts (L.X.); Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University, Rome,
Italy (F.G.)
Corresponding Author: Pinan Liu, MD, PhD, Neural Reconstructional Department, Beijing Neurosurgical Institute, Department of Neurosurgery,
Beijing Tiantan Hospital, Capital Medical University, No. 6 Tiantan Xili Dongcheng District, Beijing, China (liupinan@bjctf.org).
See the editorial by Lassaletta and Ramaswamy, on pages 895–897.
Background. Recent transcriptomic approaches have demonstrated that there are at least 4 distinct subgroups in medulloblas-
toma (MB); however, survival studies of molecular subgroups in adult MB have been inconclusive because of small sample sizes.
The aim of this study is to investigate the molecular subgroups in adult MB and identify their clinical and prognostic implications in
a large, single-institution cohort.
Methods. We determined gene expression profiles for 13 primary adult MBs. Bioinformatics tools were used to establish distinct
molecular subgroups based on the most informative genes in the dataset. Immunohistochemistry with subgroup-specific anti-
bodies was then used for validation within an independent cohort of 201 formalin-fixed MB tumors, in conjunction with a system-
atic analysis of clinical and histological characteristics.
Results. Three distinct molecular variants of adult MB were identified: the SHH, WNT, and group 4 subgroups. Validation of these
subgroups in the 201-tumor cohort by immunohistochemistry identified significant differences in subgroup-specific demograph-
ics, histology, and metastatic status. The SHH subgroup accounted for the majority of the tumors (62%), followed by the group 4
subgroup (28%) and the WNT subgroup (10%). Group 4 tumors had significantly worse progression-free and overall survival
compared with tumors of the other molecular subtypes.
Conclusions. We have identified 3 subgroups of adult MB, characterized by distinct expression profiles, clinical features, patholog-
ical features, and prognosis. Clinical variables incorporated with molecular subgroup are more significantly informative for predict-
ing adult patient outcome.
Keywords: adult medulloblastoma, histology, molecular subgroup, prognosis, survival.
Medulloblastoma (MB) is the most common malignant pediat-
ric brain tumor but accounts for ,1% of adult intracranial tu-
mors.1 Over the past 2 decades, MB survival has been improved
by considerable advancements in therapeutic strategies on the
basis of clinical risk stratification.2 However, MB is still associat-
ed with a poor outcome overall, and most survivors are left with
long-term disabilities secondary to treatment.3 – 5 Studies are
urgently needed to understand the biology of the disease,
develop novel targets, and identify biomarkers that predict
prognosis and response to treatment.
Recently, several transcriptional profiling studies have
shown that MB is not a single disease, but a collection of clini-
cally and molecularly diverse tumor subgroups. The current
consensus is that there are 4 major subgroups: wingless
(WNT), sonic hedgehog (SHH), group 3, and group 4, with dispa-
rate demographics, clinical characteristics, genetics, and
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transcriptomes.6 – 10 Due to the low incidence of MB in adults,
studies of the biological and clinical features in this age group
are limited. It has been shown that adult MB is distinct from pe-
diatric MB in genomic aberrations, histopathology, and prog-
nostic outcomes11,14,15; however, because of the lack of
knowledge in adult MB, the clinical treatment strategies for
adult MB are mainly adapted from pediatric protocols.11 – 13
Studies with combination of the clinical variables and subgroup
affiliation are urgently needed to improve patient prognostica-
tion and therapy strategy.
In this study, we performed gene expression analyses to
identify molecular subgroups of adult MB. The findings were
validated in an independent cohort of 201 adult MBs using an
immunohistochemistry (IHC)-based classification system, to
evaluate the characteristics of molecular subgroups and their
prognostic factors and to provide a basis for future therapeutic
applications.
Patients and Methods
Ethics Statement
The study was approved by the institutional review board (CWO
[commissie wetenschappelijk onderzoek, in Dutch]) of Altrecht
Psychosomatic Medicine, Zeist, the Netherlands. All patients
provided written informed consent.
Tumor Material and Patient Characteristics
All tumor samples were obtained from adult patients (aged
≥18 years at diagnosis) during initial surgery before any adju-
vant therapy, at the Neurosurgical Centre of Beijing Tiantan
Hospital, Beijing Neurosurgical Institute, Capital Medical Univer-
sity. Histological diagnoses according to the criteria of the 2007
World Health Organization (WHO) classification were confirmed
by 2 neuropathologists.16 The MB tumors were classified by his-
tology as classic (CMB), desmoplastic/nodular (DNMB), anaplas-
tic (AMB), or large cell (LCMB) (see Supplementary Fig. S1). Gene
expression analysis was performed on 13 frozen tumor tissue
samples containing all 4 histological subtypes. And an indepen-
dent cohort of paraffin-embedded samples collected from
1997 to 2014 from 201 adult patients was analyzed using
IHC. In this cohort, the mean age of all patients was 28.7
years (range: 18–61 y) and the sex ratio was 1.96:1 (male:fe-
male). A more detailed description of the tumor material and
patient characteristics of the 2 cohorts is provided in Supple-
mentary Table S1.
In the 201-case validation cohort, the patients were staged
using the classic Chang system definitions for tumor (T) and
metastasis (M) parameters.17 All patients were treated
with postoperative craniospinal irradiation (30 –36 Gy and
54– 60 Gy to a primary tumor site), except for 15 patients
who received whole-brain irradiation alone because of toxicity
reactions or problems with local facilities. Chemotherapy (4–6
cycles of carboplatin, vincristine, lomustine, or cisplatin) was
administered to 147 patients: 72 high-risk patients and 75
average-risk patients. The 201 patients in the cohort were
observed for a median of 60 months (range: 8–187 mo) from
date of diagnosis to last contact or death. There had been 58
deaths by the end of the study, and the median follow-up for
surviving patients was 74 months (range: 15–187 mo).
Biostatistics and Bioinformatics
The Agilent Whole Human Genome Oligo Microarray Kit, 4×44K
(Gene Expression Omnibus accession no. GPL6480) was used
for gene expression profiling of the samples (n¼ 13). Data
were extracted with Feature Extraction Software v10.7 (Agilent
Technologies). Raw data were normalized by Quantile algo-
rithm, Gene Spring Software v11.0 (Agilent Technologies).
Genes with a fold change ≥2 and P, .05 were selected for fur-
ther analysis. Pathway annotation was performed by Ingenuity
Systems.
Immunohistochemistry
Molecular subgroups of MB were identified by IHC using a com-
bination of 2 groups of markers7,8: (1) CTNNB1 (WNT/wingless
marker, 1:100; ab610154, BD Transduction Laboratories),
SFRP1 (SHH marker, 1:2000; ab4193, Abcam), NPR3 (subgroup
3 marker, 1:200; ab37617, Abcam), and KCNA1 (subgroup 4
marker, 1:2000; ab32433, Abcam); and (2) b-catenin (1:800;
BD #610154), GAB1 (1:50; Abcam #ab27439;), filamin A
(1:100; Fitzgerald #10R-F113A), and YAP1 (1:50; Santa Cruz
#sc-101199). Immunostaining was done on formalin-fixed
paraffin-embedded tumors after dewaxing and rehydrating
slides. Antigen retrieval was conducted by pretreatment at
958C. Endogenous peroxidase was blocked with 0.5% hydrogen
peroxide in water for 30 min.
For staining evaluation, 5 sections of each case were
evaluated independently. The percentage of positive cells was
evaluated for each protein. The pattern of expression (cytoplas-
mic, membranous, and nuclear) was recorded. All scores were
evaluated separately by 2 neuropathologists; the mean score
calculated was used to represent the whole immunoreactivity
in tumors. Tumors were considered negative for a marker if no
stained cells were detected in the 5 sections. Positive control
tissues for these antibodies were: CTNNB1, colonic carcinoma;
SFRP1, breast carcinoma; NPR3, breast carcinoma; KCNA1,
mouse brain; b-catenin, colonic carcinoma; GAB1, tonsil;
filaminA, appendix; YAP1, placenta. Substitution of the primary
antibody with phosphate-buffered saline was used as a nega-
tive control.
Statistical Analysis
The distribution of survival times was determined using
Kaplan–Meier estimates. The log-rank test was used to com-
pare survival curves between groups. Overall survival (OS) for
all analyses was defined as the time from diagnosis until
death. Progression-free survival (PFS) was defined as the time
from date of surgical resection until date of tumor progression
confirmed by imaging (or by death if no progression had been
confirmed previously).
Univariate and multivariate analyses were performed for
multiple variables with regard to impact on PFS and OS. Multi-
variate Cox regression models with the backward selection
method were performed to further assess molecular subgroups
and histological subtypes for PFS and OS, adjusted with clinical
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factors. P, .05 in univariate analysis and covariates were
deemed to be important prognostic factors. Factors with
P-values of .05 and .10 in the multivariate analysis were included
and excluded, respectively. All statistical analyses were
performed using SPSS software v19.0 (IBM). P, .01 was consid-
ered statistically significant.
Results
Transcriptomic Profiling Reveals 3 Subgroups of Adult
Medulloblastoma
Unsupervised hierarchical cluster analysis delineated 3 distinct
sample clusters: WNT, SHH, and non-WNT/non-SHH (Fig. 1A).
Support tree analysis of the clustering data indicated high con-
fidence for these 3 subgroups (90%; Fig. 1B). Pathway annota-
tion was performed to reveal characteristic gene expression
patterns for each of the clusters (see Supplementary Table S2).
WNT signaling was enriched in the WNT group tumors
(P¼ .0004, n¼ 4); SHH signaling was enriched in the SHH
subgroup (P¼ .0013, n¼ 3); and other tumors (non-WNT/
non-SHH) were characterized by overexpression of genes in-
volved in neuroactive ligand–receptor interaction and the calci-
um signaling pathway (P¼ .00017, n¼ 6).
Known marker genes of the WNT pathway (ie, WIF1, DKK1,
and DKK2) and the SHH pathway (ie, HHIP, SFRP1, and MYCN)
showed differential expression in their respective subgroups,
and the non-WNT/non-SHH group showed high levels of expres-
sion of known oncogenes (ie, OTX2, FOXG1B, and KCNA1) and
lack of MYC family expression (see Supplementary Fig. S2).6,7
An 80-gene classifier of MB subgroup signature genes was
also applied to recapitulate subgroups (see Supplementary
Fig. S3). The non-WNT/non-SHH tumors in this study were iden-
tified as belonging to subgroup 4.
The distinction of 3 stable clusters was further supported by
semi-nonnegative matrix factorization using the same
1300-gene list. Direct comparison of clustering results obtained
by hierarchical clustering and nonnegative matrix factorization
confirmed strong concordance between the independent anal-
yses (Rand index: 0.987). Subgroup-specific signature genes
Fig. 1. Gene expression profiles for 13 primary adult MBs display 3 subgroups with distinct demographics and histology. (A) Unsupervised
hierarchical clustering of 13 adult medulloblastomas based on 1300 transcripts with high standard deviation. Hierarchical clustering is
performed using average linkage and dissimilarity based on the Pearson correlation metric. Clinical features of the study population are
indicated below the dendrogram: sex (male, black; female, white), age at diagnosis (18–20 y, red; 20–40 y, white; .40 y, black), histology (C,
white; DN, black; LC/A, red), M stage (M0, white; M+, black), risk (low, white; high, black), and progression and death (no event, white; event,
black). (B) Application of consensus non-negative matrix factorization (NMF), an unsupervised bioinformatics tool for determining the number
of independent classes within an expression dataset, strongly supports the existence of 3 adult medulloblastoma subgroups.
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were identified using a multivariate permutation test restricted
on the proportion of false discoveries and one-way analysis of
variance.
Clinicopathological comparison reveals different character-
istics of the adult MB subgroups in this cohort (Fig. 1). The pa-
tient age distribution for SHH tumors is concentrated in the
range of 20 –40 years, whereas group 4 and WNT tumors
have a more widely distributed age of onset (18–55 y). Metas-
tasis was found in 3 cases of SHH/group 4 tumors. DNMBs were
mainly found to be of the SHH subgroup, and LCMB/AMBs were
only found in the SHH and group 4 subgroups. Classic histology
was found in all molecular variants.
Validation of Molecular Subgroups in Adult
Medulloblastoma by IHC
Molecular subtype-specific markers were stained in 201
formalin-fixed paraffin-embedded samples of adult MB (see
Supplementary Figs. S4 and S5). In this cohort, most adult
MBs were classified as SHH tumors (124/201, 62%), followed
by group 4 tumors (28%) and WNT tumors (10%). All 201 sam-
ples were immune-negative for NPR3. There were significant
clinical differences among the 3 molecular subgroups
(Table 1). Age distributions of the 3 subgroups are shown in
Supplementary Fig. S6. Male patients predominantly had SHH
and group 4 tumors, whereas female patients predominantly
had tumors in the WNT group (P¼ .007). SHH tumors showed
an overrepresentation of hemispheric location (P, .001), and
WNT tumors had a lower incidence of fourth ventricular floor
involvement (P, .001). Tumors with classic histology account-
ed for the largest proportion of all molecular variants, especially
in the WNT subtype, in which 95% of the tumors had classic
histology. Most DNMB tumors belonged to the SHH subtype
(P, .001). Anaplastic MBs and LCMBs were found to be only
SHH or group 4 tumors.
Clinicopathological and Molecular Prognosticators in
Adult Medulloblastoma by IHC
In the IHC-based cohort of 201 adult patients, the estimated
5-year PFS and OS rates were 60% (95% CI, 52%–67%) and
73% (95% CI, 66%–80%), respectively, and the estimated
10-year PFS and OS rates were 52% (95% CI, 45%–62%) and
65% (95% CI, 57%–73%), respectively.
Among the clinical variables, metastatic dissemination (M+
stage) at diagnosis and whole-brain irradiation alone were as-
sociated with significant unfavorable prognosis (PFS and OS, re-
spectively: P, .001; Table 2). Poorer PFS and OS were also noted
for adults with tumors located in the midline than for those
with tumors located in the hemispheres (OS: P¼ .039, PFS:
P¼ .045). There was no statistically significant survival differ-
ence between the groups with and without chemotherapy
(OS: P¼ .548; PFS: P¼ .787; Supplementary Fig. S7). Stratifica-
tion of risk classification showed that average-risk patients
had better PFS and OS than high-risk patients (PFS/OS: P,
.001; Fig. 2A and B).
Stratification of histological subtypes and molecular sub-
groups in survival rates was also observed. Compared with
the CMB and DNMB subtypes, AMBs had poorer OS and PFS
(OS/PFS: P, .001; Fig. 2C and D) and LCMBs had poorer PFS
(P¼ .024 and P¼ .001, respectively; Fig. 2C and D). Among
the 3 molecular subgroups, MBs classified as group 4 had the
most unfavorable prognosis (OS/PFS: P, .001; Fig. 2E and F).
In SHH-subgroup MB, adult patients with LCMB/AMB had poorer
prognosis than those with DNMB or CMB (OS: P ,.001; PFS:
P¼ .002; Supplementary Fig. S8A and B). In both SHH and
group 4 tumors, the survival rates of adult patients with M+
stage were lower than those of adult patients with M0 stage
(OS/PFS: P¼ .001; OS: P, .001, PFS: P¼ .002, respectively;
Supplementary Fig. S8C–F).
The multivariate Cox proportional hazards model was
applied to selected independent variables useful for OS and
PFS prediction. Radiation, metastatic disease, histological sub-
type (ie, CMB, DNMB, LCMB, or AMB) and molecular subgroup
(ie, SHH, WNT, or group 4) were identified as independent
significant predictors for PFS and OS (Table 3).
Discussion
Recent expression profiling studies have indicated the existence
of 4 major molecular subgroups associated with activation of
Table 1. Clinical characteristics of the 3 molecular subtypes of adult
medulloblastoma
Characteristic SHH
(n¼ 124)
WNT
(n¼ 20)
Group 4
(n¼ 57)
P (x2)
No. of
Patients (%)
No. of
Patients (%)
No. of
Patients (%)
Sex
Male 88 (70.97) 7 (35.00) 38 (66.67) .007
Female 36 (29.03) 13 (65.00) 19 (33.33)
Tumor location
Midline 55 (44.35) 14 (70.00) 43 (75.44) 1.9–e4
Hemisphere 69 (55.65) 6 (30.00) 14 (24.56)
Tumor size
≤4 cm 59 (47.58) 13 (65.00) 29 (50.88) .349
.4 cm 65 (52.42) 7 (35.00) 28 (49.12)
V4 floor involvement
Yes 53 (42.74) 9 (45.00) 40 (70.18) .002
No 71 (57.26) 11 (55.00) 17 (29.82)
Metastasis classification
M0 104 (83.87) 18 (90.00) 44 (77.19) .282
M+ 20 (16.13) 2 (10.00) 13 (22.81)
Surgical resection
GTR 77 (62.10) 11 (55.00) 26 (45.61) .114
STR 47 (37.90) 9 (45.00) 31 (54.39)
Histology
CMB 58 (46.77) 19 (95.00) 37 (64.91) 1.5–e6
DNMB 43 (34.68) 1 (5.00) 3 (5.26)
LC/A MB 23 (18.55) 0 (0) 17 (29.83)
Risk
Average 70 (56.45) 17 (85.00) 26 (45.61) .020
High 54 (43.55) 3 (15.00) 31 (54.39)
Abbreviations: GTR, gross total resection; STR, subtotal resection; V4,
fourth ventricle.
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specific signaling pathways in MB.6,7,18,19 The identification of
such molecular subgroups provides important opportunities
to improve our understanding of the disease and its clinical
treatment. Several studies have shown that adult and pediatric
MBs are genetically distinct and may require different algo-
rithms for molecular risk stratification.6,11,14,15,20 However,
due to the low incidence of adult MB, the lack of a common
treatment strategy, and the frequent occurrence of late relaps-
es after more than 5 years, systematic studies of the biologic
and clinical characteristics in adult MB have been hindered.
Remke et al21 identified 3 molecular subgroups in adult MB,
and tumors classified as subgroup D had worse prognosis.
Additionally, this study also showed that most clinicopatholog-
ical factors were of no statistical significance when taking
molecular variables into account.
In our study, we selected 13 adult MBs with 4 histological
subtypes and identified 3 subgroups of adult MB, characterized
by distinct expression profiles, clinical features, pathological
features, and prognosis. To determine whether the molecular
subgroups could support clinical variables for prognostication
in adult MB, these distinct molecular subsets were also con-
firmed by IHC in a large independent cohort of 201 adult MBs
treated at one institution over a 10-year period and with a me-
dian follow-up of over 60 months. Multiple clinicopathological
variables, especially including treatment strategy, were ana-
lyzed for prognostication by combining molecular subgroups.
We have demonstrated that subgroup status incorporated
with clinicopathological parameters (metastasis and histology)
and treatment strategy is more informative for predicting pa-
tient outcome.
In this cohort, our data showed a preponderance of
SHH-activated tumors (62%), followed by group 4 tumors
(28%) and WNT-activated tumors (10%). This is consistent
with previous studies which reported 50%–80% SHH tumors
of all cases,7,18,21 whereas group 4 MB is always the most com-
mon subgroup at all ages.6,9 In several studies, group 3 tumors
accounted for,2% of adult MBs.9,19,21 We found that the adult
tumors were devoid of group 3 cases, suggesting that this sub-
group may be restricted to pediatric MBs. The combination of
molecular and clinicopathological data has provided valuable
insights into the clinical features of the molecular subgroups.
Most DNMBs were found in the SHH group, to the extent that
DN histology may be considered a surrogate marker for SHH ac-
tivation in adult MBs. The preponderance of the SHH subgroup
in adult MB may explain its clinical differences from pediatric
MB, such as its higher incidence of hemispheric localization
and DN histology. The presence of severe anaplasia or the LC
subtype of MB is considered to be predictive of survival in pedi-
atric MB.22 In this study, the LC/A variant of MB accounted for
only a minority of SHH subgroup cases, and these tumors were
associated with a worse outcome than other tumors
(P, .0001). The WNT subgroup in adult MB predominantly
comprised the classic variant (accounting for 95% of cases),
and LC/A histology was rare. The sex ratio of the WNT subgroup
was obviously skewed, with a male-to-female ratio of 1:2. In
WNT tumors, there was rarely metastasis present at diagnosis;
however, the OS and PFS of this group were similar to those of
the SHH group. Because of the excellent prognosis of childhood
WNT MB with survival rates in excess of 90%,6,7,18 it seems that
adult WNT MB is quite different from pediatric WNT MB.6,7,18 No-
tably, group 4 MB in adults is associated with a high rate of
high-risk disease and LC/A histology, which may be the reason
that this subgroup has the worst outcome among all 3
subgroups.
Table 2. Univariate analysis for clinical, histopathological, and molecular variables with regard to impact on survival for adult MBs
Variables OS PFS
Hazard Ratio 95% CI P Hazard Ratio 95% CI P
Sex, male vs female 1.450 0.805–2.611 .216 1.145 0.720–1.822 .567
Tumor location, midline vs hemisphere 0.562 0.325–0.973 .039 0.633 0.404–0.990 .045
Tumor size (cm), .4 vs ≤4 1.067 0.636–1.790 .806 1.088 0.707–1.673 .703
V4 floor involvement, yes vs no 1.630 0.962–2.762 .070 1.386 0.898–2.140 .141
Metastasis, M+ vs M0 3.669 2.123–6.342 3.2e-6 3.311 2.061–5.318 7.3e-7
VP shunt, yes vs no 0.633 0.299–1.337 .230 0.677 0.367–1.248 .211
Resection, GTR vs STR 0.647 0.385–1.085 .099 0.670 0.435–1.031 .068
Radiotherapy, WBI vs CSI 4.284 2.207–8.316 1.7e-6 3.712 2.005–6.874 3.0e-5
Chemotherapy, yes vs no 0.845 0.488–1.465 .548 1.069 0.660–1.731 .787
Histology
DNMB vs classic 0.607 0.264–1.394 .239 0.480 0.234–0.986 .046
Anaplastic vs classic 1.910 1.428–2.553 1.3e-5 1.828 1.429–2.339 1.5e-6
Large cell vs classic 1.190 0.734–1.930 .480 1.406 1.029–1.920 .032
Molecular subgroup
WNT vs SHH 0.377 0.089–1.594 .185 0.376 0.116–1.217 .103
Group 4 vs SHH 1.887 1.443–2.467 3.5e-6 1.845 1.476–2.307 7.8e-8
WNT vs group 4 0.056 0.008–0.416 .005 0.091 0.027–0.308 1.2e-4
Abbreviations: CSI, craniospinal irradiation; GTR, gross total resection; STR, subtotal resection; V4, fourth ventricle; VP, ventriculoperitoneal; WBI,
whole-brain irradiation.
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In our study, we also found that M-stage significantly corre-
lated with OS and PFS in both univariate and multivariate anal-
yses and was an important prognostic predictor in adult
patients. This is consistent with previous studies that reported
localized disease (M0) at diagnosis as an independent prognos-
tic factor,11,14 and M+ patients as a high-risk group should
Fig. 2. Kaplan–Meier plots of estimated OS (left side) and PFS (right side) time distributions for the 201-tumor cohort of adult MB according to: (A,
B) risk staging: average risk vs high risk, (C, D) histology: classic vs desmoplastic/nodular vs anaplastic vs large cell, and (E, F) molecular subgroup:
WNT vs SHH vs group 4. Survival differences are calculated using continuous log-rank tests.
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receive more intensive treatment. Other conventional clinical
parameters for risk stratification (such as tumor size, location,
extent of tumor resection, and fourth ventricle floor involve-
ment) were not prognostic predictors. Previous studies were
controversial concerning whether the extent of tumor resection
is of prognostic value.5,11 – 13 In our opinion, complete resection
would result in severely reduced postoperative performance
status, especially for patients with tumor invaded in the fourth
ventricle or brainstem.
It has been demonstrated that the histopathological sub-
types of adult MB have substantially different prognoses. We
found that the presence of moderate or severe anaplasia in
adult MB was associated with markedly poorer prognosis. This
is consistent with previous studies of pediatric MB.22,23 As an in-
dependent subgroup, LCMB is a rare variant and has a poor
prognosis in pediatric studies.25,26 In our study, LCMBs were
present in 3.5% of adult MBs and had worse PFS than CMBs
and DNMBs. In early childhood cases, DNMBs have been linked
to better survival than CMBs,22 – 24 but there is no apparent dif-
ference in adult MBs.
Adjuvant chemotherapy did not correlate with prognosis in
either the overall patient population or the patients designated
as having average or high risk in this study, indicating that the
current chemotherapy regimen needs to be optimized for adult
Fig. 2. Continued
Table 3. Multivariate Cox proportional hazards model for selected clinical, histopathological, and molecular variables with regard to impact on
survival for adult medulloblastomas
Variables OS PFS
Hazard Ratio 95% CI P Hazard Ratio 95% CI P
Metastasis, M+ vs M0 0.370 0.208–0.657 0.001 0.333 0.202–0.551 1.8e-5
Radiotherapy, WBI vs CSI 5.277 2.574–10.815 5.6e-6 5.590 2.873–10.877 4.0e-7
Histology
DNMB vs classic 1.024 0.415–2.528 0.958 0.713 0.330–1.539 0.389
Anaplastic vs classic 2.645 1.422–4.920 0.002 2.537 1.506–4.274 4.7e-4
Large cell vs classic 1.335 0.309–5.772 0.699 1.807 0.698–4.678 0.223
Molecular subgroup
WNT vs SHH 0.367 0.085–1.592 0.181 0.303 0.091–1.008 0.051
Group 4 vs SHH 2.881 1.617–5.134 3.3e-4 2.720 1.686–4.389 4.1e-5
Abbreviations: CSI, craniospinal irradiation; WBI, whole-brain irradiation.
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MB patients. The efficacy of postoperative chemotherapy, with
or without postoperative radiotherapy, has been well estab-
lished in the pediatric population.3 – 5,22 – 24,27 However, its use
is still controversial in adult MB, and major questions remain
as to which subgroups could benefit from adjuvant chemother-
apy. Several studies show that postoperative chemotherapy re-
duced the risk of recurrence and death among high-risk adult
patients.12,14,28,29 In our study, chemotherapy also showed no
significant difference on PFS and OS in high-risk patients or
average-risk patients. It may be that high-dose craniospinal
irradiation reduced the prognostic significance of widespread
disease. Therefore, a larger randomized controlled clinical trial
is needed to study the outcome of postoperative chemotherapy.
The demographic and clinical differences among the sub-
groups emphasize the need for subgroup-specific trials of
novel therapies. In adult MB, a distinct risk stratification for mo-
lecular subgroups should be further developed and validated.
Given the more favorable outcome, WNT and SHH tumors
may be controlled by less intensive treatment, whereas the ter-
rible prognosis for group 4 patients indicates that more inten-
sive treatment is needed for this subgroup, especially when
metastasis is present at diagnosis. The urgent need for appro-
priate therapies for SHH tumors has already led to investigation
of specifically targeted therapies.9 In conclusion, our study
shows that histopathological and molecular subtypes are use-
ful prognostic factors for adult MB. Patients with AMB variants
or group 4 tumors have a significantly worse outcome and re-
quire more intensive treatment, although it should still be ac-
knowledged that the issues with the use of IHC include
differences in fixation and embedding procedures. We showed
that IHC markers are helpful in identification and validation of
molecular subgroups, thereby providing the level of confidence
necessary for subgroup assignment in the setting of a clinical
trial. Prognostication algorithms incorporating factors such as
clinical variables, histopathology, and molecular subtype
should be developed to guide individualized treatment for
adult MB patients.
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